2018 Nov 13;11(1):588. doi: 10.1186/s13071-018-3156-2.Kroidl I, Saathoff E, Maganga L, Makunde WH, Hoerauf A, Geldmacher C, Clowes P, Maboko L, Hoelscher M.Lancet. doi: 10.1055/a-0918-3678. Two drug combinations (either DEC or ivermectin, given with albendazole) have been recommended in most endemic areas. With the exception of well-described serious adverse events (AEs) occurring in … Lammie PJ. During this time, she also conducted field work in Singapore, Malaysia and Trinidad. The funding source had no role in the design, conduct, analysis, or interpretation of the study, nor in writing the report or submitting the paper for publication. Public Library of Science Compared with diethylcarbamazine (DEC), two small trials (56 participants) found little difference in microfilariae prevalence over an extended follow up. doi: 10.1371/journal.pntd.0004967. By continuing to browse this site you agree to us using cookies as described in Select your preferred language for Cochrane Reviews. An updated Infection can be diagnosed using tests for circulating mf (microfilaremia) or parasite antigens (antigenemia), or by ultrasound imaging to detect live adult worms.Albendazole alone, given biannually, is recommended for areas co-endemic for Both ivermectin and DEC rapidly clear mf infections and can suppress their reappearance.
To measure treatment effects, The authors found that albendazole alone or added to a microfilaricidal drug makes little or no difference to mf prevalence over two weeks to 12 months after treatment (high-certainty evidence).They do not know if there is an effect on mf density between one to six months (very low-certainty evidence) or at 12 months (very low-certainty evidence).Treatment with albendazole alone or added to a microfilaricidal drug makes little or no difference to antigenemia prevalence between six to 12 months (high-certainty evidence).The authors do not know if there is an effect on antigen density over six to 12 months (very low-certainty evidence). Treatment is a two-drug combination of albendazole and a microfilaricidal (antifilarial) drug, either diethycarbamazine (DEC) or ivermectin.
To summarize the effects of albendazole alone or in combination with antifilarial drugs for clinical treatment and community control of lymphatic filariasis.
Part of Albendazole tablets used in lymphatic filariasis treatment programs.https://www.flickr.com/photos/prefeituradeitapevi/33462574864Life cycle of parasitic worms causing lymphatic filariasis.Use of GRADE for synthesizing evidence and developing recommendations. Objectives.
2019 Mar;5(2):E65-E74. 2016 Aug 26;10(8):e0004967. This finding is consistent in trials evaluating albendazole alone, or added to DEC or ivermectin. Name must be less than 100 characters We sought reliable evidence of the effects of albendazole on the disease and the parasite. This includes using tools to assess the risks of bias in individual trials and Outcomes of interest included measures of transmission potential (mf prevalence and density), markers of adult worm infection (antigenemia prevalence and density, and adult worms detected by ultrasound) and adverse events.Using electronic searches, the authors attempted to identify all relevant trials up to January 2018 regardless of language or publication status. Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis. The data available are protected by copyright and may only be used in accordance with the Select your preferred language for Cochrane Reviews. 'Single-dose' 2-drug combinations of albendazole plus either ivermectin or DEC are superior in efficacy to single drug treatment for decreasing microfilaraemia in lymphatic filariasis. The use of albendazole in lymphatic filariasis.